Skip to main content
. 2005;2005:6–10.

Table 4.

Orders for β-blocker by order-set use for high risk patients without contraindication

N % β-Blocker None (0) Partial (1) Nonspecific (2) Specific (3) Spearman(Sig)
Phase 1 21 81% 88% of 16 60% of 5 −0.30 (p=0.19)
Phase 2 37 68% 68% of 22 70% of 10 60% of 5 −0.03 (p=0.86)
Phase 3 26 69% 33% of 6 88% of 8 100% of 1 73% of 11 0.24 (p=0.23)
Phase 4 26 77% 67% of 3 43% of 7 80% of 5 100% of 11 0.49 (p=0.01)